TxCell to chair world’s first workshop dedicated to adoptive T cell therapy with regulatory T cells

Workshop will be held at the North American Adoptive T Cell Therapy Congress in Boston on June 28, 2016, from 9am to 12pm

VALBONNE, France--()--Regulatory News:

TxCell SA (Paris:TXCL) (FR0010127662 – TXCL), a biotechnology company developing innovative, personalized cellular immunotherapies using regulatory T cells (Treg) to treat severe chronic inflammatory and autoimmune diseases, today announces that Arnaud Foussat, Chief Scientific Officer of TxCell, will chair the world’s first workshop dedicated to adoptive T cell therapy with Tregs for treating autoimmunity, inflammation and transplantation.

The panel of speakers at the workshop includes world-leading authors on the pioneering field of Tregs and CAR-Tregs. This includes Zelig Eshhar, the inventor of the CAR concept, Kate MacDonald, who recently published a unique preclinical proof-of-concept with human CAR-Treg cells, James Riley, co-founder of Tmunity, Qizhi Tang, a pioneer in the translation of Treg cell-based research to the clinic, and Ignacio Anegon, an expert in immuno-regulation.

The workshop will be held at the North American Adoptive T Cell Therapy Congress in Boston on June 28, 2016, from 9am to 12pm.

The panel will discuss the progress and challenges of clinical development of Treg cell-based therapy as well as new evidence for Treg cell therapeutic efficacy in preclinical settings. Topics will include manufacturing of Treg cell-based products, clinical trials with Tregs in autoimmunity and transplantation, generation and therapeutic efficacy of CAR-Treg cells, and new Treg subtypes showing therapeutic benefit in transplantation. The panel will also be answering questions from delegates.

The full summary is available at http://tcellcongressusa.com/workshop-day.

About TxCell – www.txcell.com

TxCell is a publicly listed biotechnology company that develops platforms for innovative, personalized T cell immunotherapies for the treatment of severe chronic inflammatory and autoimmune diseases with high unmet medical need. TxCell is the only clinical stage cellular therapy company dedicated to the science of regulatory T lymphocytes (Tregs). Tregs are a recently discovered T cell population for which anti-inflammatory properties have been demonstrated. Ovasave®, TxCell’s lead drug candidate, is currently in a Phase IIb clinical trial in refractory Crohn’s disease patients. Col-Treg, its second drug candidate, is in preclinical development for the treatment of autoimmune uveitis. Based in Sophia-Antipolis, France, TxCell is listed on Euronext Paris and currently has 50 employees.

Forward-Looking Statements - TxCell

This press release contains certain forward-looking statements relating to the business of TxCell, which shall not be considered per se as historical facts, including TxCell’s ability to develop, market, commercialize and achieve market acceptance for specific products, estimates for future performance and estimates regarding anticipated operating losses, future revenues, capital requirements, needs for additional financing. In addition, even if the actual results or development of TxCell are consistent with the forward-looking statements contained in this press release, those results or developments of TxCell may not be indicative of their in the future.

In some cases, you can identify forward-looking statements by words such as "could," "should," "may," "expects," "anticipates," "believes," "intends," "estimates," "aims," "targets," or similar words. Although the management of TxCell believes that these forward-looking statements are reasonably made, they are based largely on the current expectations of TxCell as of the date of this press release and are subject to a number of known and unknown risks and uncertainties and other factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievement expressed or implied by these forward-looking statements. In particular, the expectations of TxCell could be affected by, among other things, uncertainties involved in the development of the Company’s products, which may not succeed, or in the delivery of TxCell’s products marketing authorizations by the relevant regulatory authorities and, in general, any factor that could affects TxCell capacity to commercialize the products it develops, as well as, any other risk and uncertainties developed or identified in any public documents filed by TxCell with the AMF, included those listed in chapter 4 “Risk factors” of the 2015 document de référence approved by the AMF on May 24, 2016 under number R.16-048. In light of these risks and uncertainties, there can be no assurance that the forward-looking statements made in this press release will in fact be realized. Notwithstanding the compliance with article 223-1 of the General Regulation of the AMF (the information disclosed must be “accurate, precise and fairly presented“), TxCell is providing the information in these materials as of this press release, and disclaims any intention or obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Contacts

TxCell
Caroline Courme, +33(0) 4 97 21 83 00
IR & Communication Director
caroline.courme@txcell.com
or
Image Box – Press relations
Neil Hunter / Michelle Boxall, +44(0) 20 8943 4685
neil.hunter@imageboxpr.co.uk
michelle.boxall@imageboxpr.co.uk
or
NewCap – Investor relations
Julien Perez / Pierre Laurent, +33 (0)1 44 71 98 52
txcell@newcap.eu

Contacts

TxCell
Caroline Courme, +33(0) 4 97 21 83 00
IR & Communication Director
caroline.courme@txcell.com
or
Image Box – Press relations
Neil Hunter / Michelle Boxall, +44(0) 20 8943 4685
neil.hunter@imageboxpr.co.uk
michelle.boxall@imageboxpr.co.uk
or
NewCap – Investor relations
Julien Perez / Pierre Laurent, +33 (0)1 44 71 98 52
txcell@newcap.eu